SoluMatrix Fine Particle Technology™ makes low-dose NSAIDs possible

SoluMatrix Fine Particle Technology™ is a proprietary technology that is used to create NSAID drug particles that are approximately 10 to 20 times smaller than their original size.1

  • This reduction in particle size increases surface area, which leads to the product being quickly dissolved and rapidly absorbed
  • With SoluMatrix Fine Particle Technology™, NSAIDs are delivered at low-dose strengths with rapid absorption and low systemic exposure2‑4

The science of less

Iroko Pharmaceuticals developed low-dose SoluMatrix® NSAIDs to align with FDA and other regulatory authorities as well as several professional medical organizations’ recommendations on NSAID dosing: Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.5


  1. Data on file, Iroko Pharmaceuticals, LLC.
  2. Hussaini A, Solorio D, Young C. Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults. Clin Rheumatol. [epub ahead of print]
  3. Desjardins PJ, Olugemo K, Solorio D, Young CL. Pharmacokinetic properties and tolerability of low-dose SoluMatrix diclofenac. Clin Ther. 2015;37(2):448-461.
  4. Olugemo K, Solorio D, Sheridan C, Young CL. Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg. Postgrad Med. 2015;127(2):223-231.
  5. US Food and Drug Administration. Public health advisory – FDA announces important changes and additional warnings for COX-2 selective and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs). forPatientsand­Providers/ucm150314.htm. Published April 7, 2005. Accessed December 4, 2015.